

**ProteoTech to Present at Alzheimer's Association International  
Conference (AAIC) 2011,  
Paris, France, July 16-21, 2011**

**Kirkland, WA, July, 2011** - ProteoTech Inc. announced today that Dr. Qubai Hu, Director of Molecular Biology, will present at the 2011 Alzheimer's Association International Conference (AAIC), to be held in Paris, France, July 16-21, 2011.

Dr. Hu will present on Monday, July 18 during the poster session. Dr. Hu's presentation is entitled:

"Identification of EXEBRYL-1<sup>®</sup> and Other Novel Small Molecules as Tau Protein Aggregation Inhibitors".

EXEBRYL-1<sup>®</sup> is a small molecule compound that has been shown to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques, and tau protein Fibrils, found in Alzheimer's brains of disease victims.

About ProteoTech: ProteoTech is a private drug development company founded in 1996 located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides EXEBRYL-1<sup>®</sup> for Alzheimer's disease treatment, the Company is also in late stage pre-clinical development of *Synuclelere*<sup>™</sup> for the treatment of Parkinson's disease, *Systebryl*<sup>™</sup> for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called *Pepticlere*<sup>™</sup> for the treatment of Alzheimer's disease. For more information please see the Company web site at [www.proteotech.com](http://www.proteotech.com).